Looking to lift clinical hold, uniQure contends its gene therapy was likely not the cause of single liver cancer case

Slapped with a clinical hold from the FDA back in December, uniQure’s lead gene therapy program has sat on ice as it waited for a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Look­ing to lift clin­i­cal hold, uniQure con­tends its gene ther­a­py was like­ly not the cause of sin­gle liv­er can­cer case